Observational studyThe Journal of dermatology2025
Effectiveness and Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis in Real-World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study.
Observational study in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Clinical trials have demonstrated the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis. Real-world evidence for guselkumab in Korea is needed to establish drug safety and effectiveness under real-world practice in this population. This study assessed the effectiveness, safety, and drug survival of guselkumab in Korean patients with moderate-to-severe plaque psoriasis in a real-world clinical setting. In this prospective, non-interventional observational study conducted at 44 clinical centers in South Korea, adult patients with moderate-to-severe plaque psoriasis who would receive guselkumab per the product label were enrolled. Disease assessment was performed at visits 1 (baseline, week 0), 2 (approximately week 4), and 3-7 (approximately every 8 weeks after week 4, weeks 12-44). Between February 25, 2019 and March 25, 2022, 707 patients were enrolled and 562 (79.5%) had completed the 56-week observation period. The proportions of patients with an absolute Psoriasis Area and Severity Index (PASI) score of ≤ 3, ≤ 2, or ≤ 1 reached maximums of 96.0%, 86.7%, and 59.0%, respectively, at visit 7. A significantly greater proportion of biologic-naïve (vs. biologic-experienced) patients achieved absolute PASI ≤ 3 by visits 5-7 (p = 0.001 at visit 7) and absolute PASI ≤ 2 by visits 6-7 (p = 0.0014 at visit 7). Dermatology Life Quality Index (DLQI) scores decreased over time, with 64.1% of patients achieving DLQI 0/1 by visit 7; results were similar regardless of prior biologic therapy. The estimated drug-survival rate at 1 year was 92.7%. Adverse events (AEs) occurred in 22.5% of patients, with an incidence rate of 42.1 per 100 patient years (PY); 14 serious AEs occurred in 13 (1.8%) patients, with an incidence rate (95% confidence interval) of 2.4 (1.2-3.7) per 100 PY. Guselkumab administered under approved label conditions was effective and well-tolerated in Korean patients with moderate-to-severe plaque psoriasis in a real-world clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.